Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,068 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,062
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis123
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland198
- Alabama179
- Florida152
- Arizona150
- Massachusetts118
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,068 total
- NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18 - NCT06445517RecruitingPhase 1
ISM8207 for advanced solid tumors and B-cell lymphoma
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06456541Recruiting
Testing a new infant formula for children with cow's milk allergy
This study tests a new formula designed for children diagnosed with cow's milk allergy. It evaluates whether the formula is safe and well-tolerated.
Phoenix, ArizonaAges 3 months–12 years - NCT06453057Recruiting
TIL therapy for ovarian cancer
This trial tests a new therapy made from your own immune cells (called TILs) to fight ovarian cancer. Doctors remove some of your tumor, grow the immune cells in a lab, and then give them back to you to attack the cancer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06447597RecruitingPhase 2/Phase 3
Study of B007 for Generalized Myasthenia Gravis
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
BeijingAges 18–70 - NCT02523118Recruiting
Measuring symptoms and test results in eosinophilic gut diseases
This study looks at how eosinophilic inflammation in the esophagus and intestines affects outcomes like symptoms and test findings. It may help clinicians better understand these conditions and track what changes over time.
Phoenix, ArizonaAges 3 years+ - NCT04615221Recruiting
Study of immune rejection after uterine transplant
This study looks at why the body’s immune system may reject a transplanted uterus or a related surgery. Your results may help doctors understand rejection and improve care for future uterine transplants.
SuresnesAges 18–45 - NCT06452732Recruiting
Leukemia stem cell test for AML relapse in children
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT06458439RecruitingPhase 2
Epcoritamab with CAR T cells for large B-cell lymphoma
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06453044RecruitingPhase 2
Study of two drugs for follicular lymphoma that came back
This study tests a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) for people with follicular lymphoma that has come back or not responded to previous treatment. The goal is to see if this two-drug approach can help shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT06452654RecruitingPhase 4
Vaccine to prevent type 1 diabetes in high-risk babies
This study tests whether a vaccine given to very young babies (3–4 months old) can prevent type 1 diabetes. It is designed for babies who have a high genetic risk and a family history of the disease.
ViennaAges 3 months–4 months - NCT06447974Recruiting
Environmental health clinic for children with breathing problems
This study tests whether a children's environmental health clinic can help families manage chronic respiratory conditions like asthma. It focuses on your child's home environment and provides follow-up support.
LondonAges 4–17 - NCT06456450Recruiting
Taiwan severe asthma biologic registry study
This study is creating a registry to track the long-term safety and effectiveness of biologic treatments for severe asthma in Taiwan. If you are taking a biologic like omalizumab, mepolizumab, or benralizumab, joining this registry helps doctors learn how well these medicines work over time.
TaichungAges 18 years+ - NCT06457789Recruiting
PET scans to track immune response in lung cancer treatment
This study uses special PET scans to see how well your immune cells respond to immunotherapy given before surgery for non-small cell lung cancer. The goal is to learn which patients benefit most from this treatment approach.
Amsterdam, North HollandAges 18 years+ - NCT06447376RecruitingPhase 1
Testing siltuximab before epcoritamab to prevent cytokine release syndrome
This trial tests whether giving siltuximab before epcoritamab can help prevent or reduce cytokine release syndrome (a possible side effect where the immune system overreacts). It is for people with certain types of non-Hodgkin lymphoma that have not responded well to at least two prior treatments.
Cleveland, OhioAges 18–65 - NCT06453915RecruitingEarly Phase 1
Brain PET scan for inflammation in fatty liver disease
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
Sacramento, CaliforniaAges 18 years+ - NCT06455319RecruitingPhase 2
Personalized ATG with or without verapamil for new type 1 diabetes
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
Aurora, ColoradoAges 6–35 - NCT06450418Recruiting
Digital app for speech and health monitoring
This trial tests a digital app that tracks speech and health changes. It is open to people with certain neurological conditions, their caregivers, and healthy volunteers.
EdinburghAges 16 years+ - NCT06441617Enrolling by invitation
Online program to reduce fatigue in multiple sclerosis
This trial tests an online self-management program to help reduce fatigue in people with MS. You'll use a website or app over 24 weeks, and researchers will check how well it works.
Washington D.C., District of ColumbiaAges 22 years+ - NCT06458075Recruiting
Improving communication and medication adherence in lupus
This study tests whether helping lupus patients and their doctors communicate better leads to taking medications more consistently. Participants will have their doctor visits recorded and use a phone app to track their medicines.
Durham, North CarolinaAges 18–90 - NCT06450925RecruitingPhase 2
Vitamin A supplement for stem cell transplant patients
This study tests whether giving vitamin A by mouth to adults before and after a stem cell transplant can help their recovery. The goal is to see if it reduces complications and improves overall outcomes.
Tampa, FloridaAges 18 years+ - NCT06449885Recruiting
Observational study for newly diagnosed MZL
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06453694RecruitingPhase 2
Efgartigimod for first-time optic neuritis
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
Boston, MassachusettsAges 18 years+ - NCT06446661Recruiting
Text message reminders for ALL oral chemo
This study tests whether text message reminders can help patients stick to their daily oral chemotherapy schedule during the maintenance phase of ALL treatment. Participants receive friendly text reminders and can ask questions, aiming to make managing treatment easier.
Chicago, IllinoisAges 15 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,068 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,217 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.